Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy. - Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy.

Department of Urology, Saitama Medical Center, Saitama Medical University0 个研究点目标入组 5 人开始时间: 2014年9月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients 1) have a treatment history of paclitaxel treatment 2) have an allergy to albumin 3) have a heavy infection 4) have severe complications: interstitial pulmonary fibrosis, gastrointestinal hemorrhage, ileus, uncontrollable diabetes mellitus, cardiovascular disease, etc. 5) have an uncontrollable pleural, ascites or pericardial effusion. 6) have an active cancer except urothelial cancer: cancer free duration < 5 years. 7) have a brain metastasis with symptoms requiring steroids or anti-seisure medications 8) have a history of salvage radiation to primary organ or lymph node metastasis within two weeks. 9) do not meet the inclusion criteria due to mental disorders or neurological symptoms 10) have no intention to birth control 11) disqualified by a doctor in charge

发起方

Department of Urology, Saitama Medical Center, Saitama Medical University